Medtronic plc. Ordinary Shares (MDT): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDT POWR Grades
- MDT scores best on the Stability dimension, with a Stability rank ahead of 91.49% of US stocks.
- MDT's strongest trending metric is Growth; it's been moving up over the last 199 days.
- MDT ranks lowest in Momentum; there it ranks in the 15th percentile.
MDT Stock Summary
- MDT has a higher market value than 98.77% of US stocks; more precisely, its current market capitalization is $171,609,673,423.
- Medtronic plc's stock had its IPO on January 1, 1986, making it an older stock than 92.84% of US equities in our set.
- The volatility of Medtronic plc's share price is greater than that of merely 8.6% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Medtronic plc are TMUS, NVO, TXN, SAP, and TMO.
- MDT's SEC filings can be seen here. And to visit Medtronic plc's official web site, go to www.medtronic.com.
MDT Stock Price Chart Interactive Chart >
MDT Price/Volume Stats
|Current price||$126.70||52-week high||$132.30|
|Prev. close||$127.30||52-week low||$87.68|
|Day high||$128.44||Avg. volume||4,645,961|
|50-day MA||$122.17||Dividend yield||1.83%|
|200-day MA||$112.47||Market Cap||170.80B|
Medtronic plc. Ordinary Shares (MDT) Company Bio
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The company was founded in 1949 and is based in Dublin, Ireland.
MDT Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
Below please find a table outlining a discounted cash flow forecast for MDT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Medtronic plc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Medtronic plc, consider:
- Its compound free cash flow growth rate, as measured over the past 5.49 years, is 0% -- higher than merely 22.55% of stocks in our DCF forecasting set.
- The company has produced more trailing twelve month cash flow than 90.99% of its sector Healthcare.
- Medtronic plc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
MDT Latest News Stream
|Loading, please wait...|
MDT Latest Social Stream
View Full MDT Social Stream
Latest MDT News From Around the Web
Below are the latest news stories about Medtronic plc that investors may wish to consider to help them evaluate MDT as an investment opportunity.
ROSEMONT, Ill. , May 5, 2021 /PRNewswire/ -- The American Association of Neurological Surgeons (AANS) and the American Academy of Orthopaedic Surgeons (AAOS) announced that Medtronic, a global leader in medical technology, has become the latest industry sponsor of the American Spine Registry . Medtronic's sponsorship of the ASR builds upon its commitment to advancing the science of spine care and improving spine surgery outcomes with a shared goal of improving patient care. "The American Spine Registry is building momentum," said Steven Glassman , MD, FAAOS, medical director at the Norton Leatherman Spine Centers and ASR Executive Committee co-chair. "By engaging the expertise and leadership of industry sponsors like Medtronic, we can enhance the scalability, sustainability, ease-of-use...
Top US corporates have come together to supply much needed ventilators and oxygen concentrators to India. The first batch landed on Wednesday and supplies are expected to come in consistently over the next month. Some of the biggest industry names, including Accenture, Amazon, Apple, Deloitte, Mastercard, Walmart, IBM and Lockheed Martin have joined hands to bring in equipment.Led by the US Chambers of Commerce, the initiative will bring in at least 1,000 ventilators for ICU beds across India and will ship in over 25,000 concentrators that can be used to set up mobile healthcare units, specially in rural areas where access is limited.“The global taskforce for pandemic response was created to meet the urgent needs of the Indian Covid-19 crisis, in a structured manner to ensure that priva...
In this article you are going to find out whether hedge funds think Medtronic plc (NYSE:MDT) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]
Medtronic Announces CE Mark of Evolut™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark of the Evolut™ PRO+ TAVI System – the newest-generation Medtronic TAVI system that builds off the proven self-expanding, supra-annular Evolut TAVI platform. The Evolut PRO+ TAVI System includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest annular range (for self-expanding TAVI technology) on the market. The approval follows a recent indication expansion for the Evolut platform in Europe for patients with severe aortic stenosis who are at a low risk of surgical mortality and patients with bicuspid aortic valves who are at intermediate, high and extreme risk of surgical mortality.
Procedure-Related Techniques and Care Pathways from the OPTIMIZE PRO Clinical Study Show Promising Early Outcomes for Patients Implanted with the Medtronic Evolut™ TAVR System
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced results from an interim analysis of the first 171 patients (including 71 roll-ins) treated in the OPTIMIZE PRO clinical study. The post-market, prospective, multi-center study is evaluating procedural outcomes (including pacemaker rate) associated with procedure-related techniques and post-procedure TAVR care pathways when using the self-expanding, supra-annular Evolut™ PRO and PRO+ TAVR systems in patients with symptomatic severe aortic stenosis. The interim data was presented virtually at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions.
MDT Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|